1. CDC. Heart Failure Fact Sheet. Division for Heart Disease and Stroke Prevention 2019; Available from: https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm
  2. Ajlan, M., et al., Atrial Fibrillation in Patients Hospitalized With Heart Failure: Patient Characteristics and Outcomes From the HEARTS Registry. Angiology, 2018. 69(2): p. 151-157.
  3. Al-Khatib, S.M., et al., Non-evidence-based ICD implantations in the United States. JAMA, 2011. 305(1): p. 43-49.
  4. Jalnapurkar, S., et al., A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. American heart journal, 2018. 200: p. 127-133.
  5. Kramer, D.B., et al., Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR. Circulation. Cardiovascular quality and outcomes, 2013. 6(4): p. 488-497.
  6. Lindvall, C., et al., National Trends in the Use of Cardiac Resynchronization Therapy With or Without Implantable Cardioverter-Defibrillator. Circulation, 2016. 133(3): p. 273-281.
  7. Patel, N., et al., Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. JACC. Heart failure, 2016. 4(5): p. 348-356.
  8. Shah, K.S., et al., Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. Journal of the American College of Cardiology, 2017. 70(20): p. 2476-2486.
  9. Spinar, J., et al., Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Critical care (London, England), 2011. 15(6): p. R291-R291.
  10. Yancy, C.W., et al., 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017. 136(6): p. e137-e161.
  11. Zhan, C., et al., Cardiac device implantation in the United States from 1997 through 2004: a population-based analysis. Journal of general internal medicine, 2008. 23 Suppl 1(Suppl 1): p. 13-19.
  12. FDA PMA Approval link: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id-P18005o
  13. Zile MR et al Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct17(1o):1066-74
  14. Gronda E et al Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail. 2014 Sep16(9):977-83
  15. Zile MR et al Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. 2020 Jul, 76 (1) 1-13